| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S13277-015-3184-X |
| P698 | PubMed publication ID | 25663495 |
| P50 | author | Mohammad Hojjat-Farsangi | Q38543823 |
| P2093 | author name string | Mohammad Hojjat-Farsangi | |
| P2860 | cites work | Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia | Q24203027 |
| Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway | Q24299670 | ||
| Mammalian target of rapamycin: a central node of complex signaling cascades | Q24601702 | ||
| Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling | Q24608960 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling | Q24672058 | ||
| Cytoplasmic components in hepatic cell lysosomes | Q24683078 | ||
| Lenalidomide and chronic lymphocytic leukemia | Q26823597 | ||
| Autophagy in stem cells | Q26823995 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| AXL kinase as a novel target for cancer therapy | Q26863442 | ||
| Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogs | Q26991440 | ||
| Jakpot! New small molecules in autoimmune and inflammatory diseases | Q27001957 | ||
| Autophagy: an adaptive metabolic response to stress shaping the antitumor immunity | Q38231982 | ||
| The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy | Q38234650 | ||
| An emerging role for long non-coding RNAs in cancer metastasis | Q38237645 | ||
| Targeting hypoxia in the treatment of small cell lung cancer | Q38247252 | ||
| Combining immunotherapy and radiation for prostate cancer | Q38275651 | ||
| Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment | Q38714409 | ||
| Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. | Q38949999 | ||
| Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer | Q39132654 | ||
| Potent antimyeloma activity of a novel ERK5/CDK inhibitor | Q39175113 | ||
| Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing | Q39587350 | ||
| Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas | Q39852196 | ||
| A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth | Q39922975 | ||
| Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment | Q39943631 | ||
| Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. | Q40158513 | ||
| Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model | Q40427861 | ||
| Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism | Q41857469 | ||
| Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells | Q42446777 | ||
| Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. | Q42679996 | ||
| Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas | Q42721017 | ||
| Trial Watch: Lenalidomide-based immunochemotherapy | Q42737828 | ||
| Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma | Q42923456 | ||
| Immunomodulatory drug costimulates T cells via the B7-CD28 pathway | Q44598249 | ||
| Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. | Q45876740 | ||
| IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. | Q45964133 | ||
| A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors | Q46152278 | ||
| Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. | Q46375251 | ||
| Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity | Q46648636 | ||
| Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. | Q47959631 | ||
| Splicing factor SF3b as a target of the antitumor natural product pladienolide | Q50672786 | ||
| Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma | Q51051144 | ||
| microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway | Q51696218 | ||
| Radiosensitization by nitric oxide at low radiation doses | Q51798691 | ||
| Identification of a cis-acting element in the rat alpha-fetoprotein gene and its specific binding proteins in F9 cells during retinoic acid-induced differentiation | Q52179275 | ||
| Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy | Q53130253 | ||
| Bcl-2 family proteins are essential for platelet survival | Q53581386 | ||
| MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma | Q54189779 | ||
| Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. | Q54543857 | ||
| Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome | Q54592967 | ||
| Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. | Q54710993 | ||
| A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation | Q57569610 | ||
| Cure of Mice Bearing Advanced Plasma Cell Tumours With Aniline Mustard | Q59074987 | ||
| Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity | Q59076491 | ||
| Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia | Q64375929 | ||
| Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid) | Q67915608 | ||
| Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens | Q73798453 | ||
| Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma | Q79177549 | ||
| Alemtuzumab | Q81501644 | ||
| Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein | Q83554118 | ||
| Transplantation: alemtuzumab induction is safe for renal transplant recipients | Q84448657 | ||
| Targeting double-stranded RNA with spermine, 1-naphthylacetyl spermine and spermidine: a comparative biophysical investigation | Q85243392 | ||
| Statins, autophagy and cancer metastasis | Q38059425 | ||
| Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. | Q38097867 | ||
| Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases | Q38105361 | ||
| Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy | Q38107961 | ||
| Update on Therapeutic Options for Multiple Sclerosis | Q38125058 | ||
| TGF-beta signaling in cancer treatment | Q38128874 | ||
| Systemic treatment options for untreated patients with metastatic clear cell renal cancer. | Q38131133 | ||
| New drugs and targeted treatments in Hodgkin's lymphoma | Q38149597 | ||
| Monoclonal antibody-related drugs for cancer therapy | Q38165692 | ||
| The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation | Q38178500 | ||
| Cracking the survival code: autophagy-related histone modifications | Q38178832 | ||
| Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next | Q38204386 | ||
| Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer | Q38214511 | ||
| Targeted biopharmaceuticals for cancer treatment | Q38228647 | ||
| New and emerging HDAC inhibitors for cancer treatment | Q27022413 | ||
| Developments in the identification of glycan biomarkers for the detection of cancer | Q27026715 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| A tumorigenic subpopulation with stem cell properties in melanomas | Q28277490 | ||
| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma | Q28649793 | ||
| Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing | Q29547470 | ||
| Glycosylation in cellular mechanisms of health and disease | Q29617310 | ||
| Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma | Q30615908 | ||
| Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 | ||
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer | Q33400716 | ||
| A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors | Q33401052 | ||
| Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. | Q33402561 | ||
| Romidepsin for the treatment of T-cell lymphomas | Q33408509 | ||
| Targeted immunotherapy for non-small cell lung cancer | Q33585089 | ||
| Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | Q33847401 | ||
| The induction of differentiation in teratocarcinoma stem cells by retinoic acid | Q33851753 | ||
| Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. | Q33852396 | ||
| Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells | Q33977987 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| How does interferon-alpha exert its antitumour activity in multiple myeloma? | Q34122885 | ||
| Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies | Q34158454 | ||
| CD20: a gene in search of a function. | Q34166779 | ||
| Regulation of terminal differentiation of cultured human keratinocytes by vitamin A. | Q34249213 | ||
| Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. | Q34257912 | ||
| Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. | Q34260686 | ||
| MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel | Q34293127 | ||
| Novel clinical therapeutics targeting the epithelial to mesenchymal transition | Q34345818 | ||
| Campath-1H. | Q34567960 | ||
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia | Q34617307 | ||
| Alemtuzumab Induction in Renal Transplantation | Q34660489 | ||
| Retracted: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells | Q34674715 | ||
| The CD52 antigen and development of the CAMPATH antibodies | Q34780507 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. | Q34975423 | ||
| Treatment of fludarabine-refractory chronic lymphocytic leukemia | Q34978317 | ||
| Development of polyamine analogs as cancer therapeutic agents | Q35055834 | ||
| Bruton's TK inhibitors: structural insights and evolution of clinical candidates | Q35181271 | ||
| A functional screen identifies miRs that induce radioresistance in glioblastomas | Q35285532 | ||
| Identification of small molecule inhibitors of pre-mRNA splicing | Q35301222 | ||
| Nonconventional chemical inhibitors of microRNA: therapeutic scope | Q35346350 | ||
| Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia | Q35848726 | ||
| New anticancer strategies targeting HIF-1. | Q35864024 | ||
| Activation of the Aryl Hydrocarbon Receptor AhR Promotes Retinoic Acid–Induced Differentiation of Myeloblastic Leukemia Cells by Restricting Expression of the Stem Cell Transcription Factor Oct4 | Q36080617 | ||
| Immunomodulatory drugs. | Q36321396 | ||
| Inhibition of TGFbeta signaling in cancer therapy | Q36353153 | ||
| Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases | Q36803757 | ||
| Analysis of the E-cadherin repressor Snail in primary human cancers. | Q36857869 | ||
| Update on anti-CTLA-4 antibodies in clinical trials | Q36909389 | ||
| Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. | Q37121130 | ||
| Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer | Q37174362 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia | Q37559275 | ||
| APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase | Q37577458 | ||
| Targeting the hypoxia-inducible factor (HIF) pathway in cancer. | Q37587446 | ||
| Chemotherapy: managing side effects and safe handling. | Q37590118 | ||
| Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma | Q37626685 | ||
| Targeting metabolic transformation for cancer therapy. | Q37714309 | ||
| Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy | Q37777312 | ||
| The molecular physiology of nuclear retinoic acid receptors. From health to disease | Q37802557 | ||
| Retinoids, Retinoic Acid Receptors, and Cancer | Q37809078 | ||
| Novel agents for the treatment of chronic lymphocytic leukemia | Q37843413 | ||
| Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly | Q37844139 | ||
| Autophagy: cancer therapy's friend or foe? | Q37855922 | ||
| Ridaforolimus: A Promising Drug in the Treatment of Soft-Tissue Sarcoma and Other Malignancies | Q37898105 | ||
| Rituximab for chronic lymphocytic leukemia | Q37988562 | ||
| Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions | Q38003390 | ||
| Endogenous anticancer mechanism differentiation | Q38015191 | ||
| EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. | Q38040369 | ||
| New strategies for targeting the hypoxic tumour microenvironment in breast cancer | Q38051945 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 543-556 | |
| P577 | publication date | 2015-02-09 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Novel and emerging targeted-based cancer therapy agents and methods | |
| P478 | volume | 36 |
| Q38680431 | Epigenetic alternations and cancer chemotherapy response |
| Q64971959 | Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. |
| Q38585329 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. |
| Q90655135 | MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells |
| Q38828353 | Mechanisms of tumor cell resistance to the current targeted-therapy agents. |
| Q38955246 | Recent advances in targeting mTOR signaling pathway using small molecule inhibitors |
| Q42686091 | Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors |
| Q38554422 | Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances |
| Q38601568 | Targeting tumor suppressor genes for cancer therapy |
| Q92480130 | Therapeutic enquiries about biological agents as a tool to identify safety aspects and patterns of use |
Search more.